In its Q2 2017 Earnings Call last week, Momenta reported that it continues to work towards a first submission for approval of its wholly owned HUMIRA biosimilar, M923, with a possible commercial launch by 2020. Momenta also reported that it is looking for potential collaborators as it further develops M923.
In collaboration with Mylan, Momenta is also developing an ORENCIA biosimilar candidate, M834. M834 is currently in Phase I trials and Momenta expects updates on those results by the second half of this year. Phase III study plans are still in development but Momenta expects to launch in the U.S. as early as 2020.
Finally, Momenta are is developing another biosimilar product, M710, although Momenta has not yet disclosed the referenced brand drug. Momenta estimates that the first regulatory submission for M710 will be in late 2017 or early 2018. Momenta plans to disclose this biosimilar candidate closer to that time frame.
